Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11337111 | 0.76 | TP53 (0.44) | NOS2ALDH1A1TRPA1CYP3A4MIF | |
| SCHEMBL7430259 | 0.76 | HIF1A (0.47) | ALDH1A1TRPA1MIFHPGDTSHR | |
| SCHEMBL6598540 | 0.73 | TSHR (0.50) | NOS2ALDH1A1TRPA1CYP3A4MIF | |
| SCHEMBL4762887 | 0.73 | TRPA1 (0.41) | NOS2ALDH1A1TRPA1CYP3A4MIF | |
| SCHEMBL1653 | 0.72 | ALDH1A1 (0.55) | NOS2ALDH1A1TRPA1CYP3A4MIF | |
| SCHEMBL1852892 | 0.71 | ALDH1A1 (0.40) | NOS2ALDH1A1TRPA1CYP3A4MIF | |
| SCHEMBL10667652 | 0.71 | TSHR (0.44) | NOS2ALDH1A1TRPA1CYP3A4MIF | |
| SCHEMBL2270 | 0.70 | — | — | |
| SCHEMBL4589447 | 0.70 | GRIN2B (0.42) | NOS2ALDH1A1TRPA1CYP3A4MIF | |
| SCHEMBL7462793 | 0.70 | TRPA1 (0.39) | NOS2ALDH1A1TRPA1CYP3A4MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108780273-B | Photosensitive colored resin composition, color filter and manufacturing method thereof, and display device | DNP精细化工股份有限公司 | 2022-06-28 | — | — | CN | claimed |
| CN-106831575-B | A kind of preparation method of 1- aminoisoquinoline -6- methanol | 北京六合宁远科技有限公司 | 2019-04-16 | — | — | CN | claimed |
| CN-106905280-A | Hesperetin analog derivative of a kind of amide groups substitution and preparation method thereof and as the application in the medicine of anti-alzheimer's disease | 安徽医科大学 | 2017-06-30 | — | — | CN | claimed |
| EP-1867645-B1 | Variolin derivatives and their use as antitumor agents | PHARMA MAR SA (ES) | 2010-09-08 | — | — | EP | claimed |
| US-7772241-B2 | Variolin derivatives and their use as antitumor agents | PHARMA MAR S.A. (ES) | 2010-08-10 | — | — | US | claimed |
| US-7745450-B2 | Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy | INSTITUTE OF EXPERIMENTAL BOTANY (CZ) | 2010-06-29 | — | — | US | claimed |
| WO-2010063487-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-06-10 | — | — | WO | claimed |
| US-7652022-B2 | N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; | NOVARTIS AG (CH) | 2010-01-26 | — | — | US | claimed |
| US-20090197901-A1 | VARIOLIN DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | PHARMA MAR, S.A. (ES) | 2009-08-06 | — | — | US | claimed |
| EP-2049507-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AND/OR AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | Brystol-Myers Squibb Company (US) | 2009-04-22 | — | — | EP | claimed |
| EP-1404668-A1 | VARIOLIN DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | PHARMA MAR, S.A. (ES) | 2004-04-07 | — | — | EP | claimed |
| WO-2003099771-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2003-12-04 | — | — | WO | claimed |
| EP-1299388-A1 | VARIOLIN DERIVATIVES AS ANTI-CANCER AGENTS | PHARMA MAR, S.A. (ES) | 2003-04-09 | — | — | EP | claimed |
| WO-2003006457-A1 | VARIOLIN DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | PHARMA MAR, S.A. (ES) | 2003-01-23 | — | — | WO | claimed |
| WO-2002004447-A1 | VARIOLIN DERIVATIVES AS ANTI-CANCER AGENTS | PHARMA MAR, S.A. (ES) | 2002-01-17 | — | — | WO | claimed |
| WO-1994000432-A1 | ANORECTIC EPINEPHRINE DERIVATIVES | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-01-06 | — | — | WO | claimed |
| US-4880840-A | ANIMAL GROWTH REGULATORS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-11-14 | — | — | US | claimed |
| US-4617401-A | ANTISPASMODIC AGENTS, VASODILATORS | SUNTORY LTD. (JP) | 1986-10-14 | — | — | US | claimed |
| US-4268510-A | DEMETHANIZATION, METABOLISM, RUMEN | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1981-05-19 | — | — | US | claimed |
| EP-0010348-A1 | Heterocyclic trichloromethyl derivatives, process for their preparation and their use | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1980-04-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197901-A1 | VARIOLIN DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | CBR3, CCNL2, HRH3 | NOS2 382/4885ALDH1A1 2783/4885TRPA1 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.